---
title: "Final Update Antipsychotics Project"
subtitle: "IÂ´m so glad &#x1F602;&#x1F44F;"
format: 
  revealjs:
    theme: [default, custom.scss]
    slide-number: true
editor: source
incremental: true

---
## Differentially Methylated Regions <br> associated with antipsychotic treatment <br> <br> <br> <br> <br> Martens Summer Seminar <br> June 17, 2024 {background-color="black" background-image="img/summerFlowers.jpg" background-size="cover" background-opacity="0.7"}



## Looking back <br>

-   Focus on response, rather than cross-sectional methylation status
-   Real-world studies are also challenging
-   Median study duration 6 weeks, maximum 13 weeks (PMID:37159349)
-   Treatment discontinuation rate (TDR) lower for monotherapy vs polypharmacy
-   Risperidone highest TDR and shortest Time to discontinuation (TTD) (PMID: 35770081)

::: footer
Leucht et al.(2013) **World Psychiatry**; Zhang et al.(2022) **Frontiers in Pharmacology**, 2022
:::

## Sample Selection {.smaller}

:::: columns

::: {.column width="40%"}

![](img/Sample_Selection.500.png){.absolute top=90 width=300px}

:::

::: {.column width="60%"}
<br>
<p>[SCZ, BPD, MDD]{.highlight}</p>

<br> Same monotherapy AP samples for both groups <br><br> Olanzapine, Quetiapine, Risperidone <br><br> Included Med-free in Specific Effects group    

:::

::::

## Differentially Methylated Regions 

:::: columns

:::{.column width="70%"}

![](img/CommonEffectsDMRsb.png)

:::

::: {.column width="30%"}

<br> Common Effects <br><br> Meta-analysis EWAS results <br><br> n = 136

:::

::::

##


